Literature DB >> 2084073

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

R Motzer1, H Scher, D Bajorin, C Sternberg, G J Bosl.   

Abstract

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2084073     DOI： 10.1007/BF00198598

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  3 in total

1.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

2.  Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.

Authors:  F A Dorr; J G Kuhn; J Phillips; D D von Hoff
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

3.  Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.

Authors:  K L Rinehart; J B Gloer; R G Hughes; H E Renis; J P McGovren; E B Swynenberg; D A Stringfellow; S L Kuentzel; L H Li
Journal:  Science       Date:  1981-05-22       Impact factor: 47.728
  3 in total
  2 in total

Review 1.  Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Authors:  D M Shin; P Y Holoye; A Forman; R Winn; R Perez-Soler; S Dakhil; J Rosenthal; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Phase II study of didemnin B in advanced colorectal cancer.

Authors:  D V Jones; J A Ajani; R Blackburn; K Daugherty; B Levin; Y Z Patt; J L Abbruzzese
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.